Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.22B P/E - EPS this Y 1.70% Ern Qtrly Grth -
Income -220.31M Forward P/E -6.79 EPS next Y 31.90% 50D Avg Chg 8.00%
Sales 295.21M PEG -0.08 EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book 1.74 EPS next 5Y 150.00% 52W High Chg -64.00%
Recommedations 2.10 Quick Ratio 4.37 Shares Outstanding 58.59M 52W Low Chg 87.00%
Insider Own 1.72% ROA -16.39% Shares Float 57.70M Beta 1.76
Inst Own 109.18% ROE -38.36% Shares Shorted/Prior 8.94M/9.21M Price 21.39
Gross Margin 40.53% Profit Margin -74.63% Avg. Volume 1,268,609 Target Price 53.49
Oper. Margin -54.00% Earnings Date Nov 15 Volume 1,361,700 Change -6.55%
About Twist Bioscience Corporation

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Twist Bioscience Corporation News
12/19/24 Twist Bioscience to Present at 43rd Annual J.P. Morgan Healthcare Conference
12/16/24 Twist Bioscience (TWST) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
12/12/24 Is Alvotech (ALVO) Stock Outpacing Its Medical Peers This Year?
12/11/24 Why Twist Bioscience (TWST) Is the Worst ARK Stock to Buy According to Short Sellers
11/27/24 Twist Bioscience named a Best Idea for 2025 at TD Cowen
11/26/24 Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?
11/20/24 Twist Bioscience Full Year 2024 Earnings: EPS Misses Expectations
11/19/24 Twist Bioscience price target lowered to $52 from $55 at Barclays
11/19/24 Twist Bioscience Corporation (TWST): Among the Best Genomics Stocks to Buy Right Now
11/19/24 Company News for Nov 19, 2024
11/19/24 Q4 2024 Twist Bioscience Corp Earnings Call
11/19/24 Twist Bioscience Corp (TWST) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...
11/18/24 Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps
11/18/24 Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
11/18/24 Twist Bioscience: Fiscal Q4 Earnings Snapshot
11/18/24 Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results
11/14/24 Twist Bioscience to Present at 7th Annual Evercore HealthCONx Conference
11/07/24 Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
11/04/24 Adma Biologics (ADMA) Soars 18.8%: Is Further Upside Left in the Stock?
10/31/24 Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Green Paula SVP of Human Resourc.. SVP of Human Resources Sep 16 Option 5.95 8,514 50,658 22,610 09/20/22
Green Paula SVP of Human Resourc.. SVP of Human Resources Sep 16 Sell 37.43 8,514 318,679 14,199 09/20/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Aug 16 Option 11.59 9,000 104,310 47,831 08/18/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Aug 16 Sell 50.06 13,900 695,834 38,831 08/18/22
Banyai William See Remarks See Remarks Jul 22 Sell 43.19 378 16,326 258,729 07/26/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Apr 14 Option 20.53 6,620 135,909 53,308 04/18/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Apr 14 Sell 43.12 6,620 285,454 46,688 04/18/22
Banyai William See Remarks See Remarks Apr 01 Sell 53.61 318 17,048 262,455 04/05/22
Banyai William See Remarks See Remarks Feb 18 Sell 52.66 1,280 67,405 263,073 02/23/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Feb 18 Option 25 3,517 87,925 51,442 02/23/22
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Feb 18 Sell 52.86 4,442 234,804 47,000 02/23/22
Banyai William See Remarks See Remarks Jan 24 Sell 54.73 348 19,046 265,174 01/26/22
Banyai William See Remarks See Remarks Oct 22 Sell 117.39 19,791 2,323,265 306,378 10/26/21
Leproust Emily M. President & CEO President & CEO Oct 21 Option 5.95 1,740 10,353 174,222 10/25/21
Leproust Emily M. President & CEO President & CEO Oct 21 Sell 120.99 1,740 210,523 172,482 10/25/21
Weiss Patrick Chief Operating Offi.. Chief Operating Officer Oct 13 Option 20.17 4,906 98,954 53,902 10/15/21
Weiss Patrick Chief Operating Offi.. Chief Operating Officer Oct 13 Sell 104 4,906 510,224 48,996 10/15/21
Banyai William See Remarks See Remarks Oct 13 Option 7.39 28,181 208,258 326,457 10/15/21
Leproust Emily M. President & CEO President & CEO Oct 13 Option 5.95 1,740 10,353 174,222 10/15/21
Leproust Emily M. President & CEO President & CEO Oct 13 Sell 110.16 1,740 191,678 172,482 10/15/21
Leproust Emily M. President & CEO President & CEO Oct 06 Option 5.95 8,700 51,765 174,222 10/08/21
Leproust Emily M. President & CEO President & CEO Oct 06 Sell 99.05 8,700 861,735 172,482 10/08/21
Leproust Emily M. President & CEO President & CEO Sep 13 Sell 118.46 29,587 3,504,876 219,143 09/13/21
Leproust Emily M. President & CEO President & CEO Sep 13 Option 7.39 29,587 218,648 233,063 09/13/21
JOHANNESSEN JAN Director Director Aug 20 Option 14 5,000 70,000 6,898 08/20/21
JOHANNESSEN JAN Director Director Aug 20 Sell 97.11 5,000 485,550 1,898 08/20/21
Weiss Patrick Chief Operating Offi.. Chief Operating Officer May 21 Option 20.17 4,905 98,934 57,109 05/21/21
JOHANNESSEN JAN Director Director May 21 Option 14 5,000 70,000 6,898 05/21/21
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Apr 26 Option 11.59 5,000 57,950 53,034 04/26/21
THORBURN JAMES M Chief Financial Offi.. Chief Financial Officer Apr 26 Sell 133.47 5,000 667,350 48,034 04/26/21
Leproust Emily M. President & CEO President & CEO Apr 15 Sell 128.84 2,000 257,680 265,843 04/15/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Apr 07 Option 19.6 2,702 52,959 45,446 04/07/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Apr 07 Sell 126.72 2,702 342,397 42,744 04/07/21
Daniels Mark See Remarks See Remarks Feb 26 Option 23.33 620 14,465 67,546 02/26/21
Daniels Mark See Remarks See Remarks Feb 26 Sell 134.31 620 83,272 66,926 02/26/21
Banyai William See Remarks See Remarks Feb 24 Sell 144.18 20,275 2,923,250 440,987 02/24/21
Leproust Emily M. President & CEO President & CEO Feb 11 Sell 178.43 75,000 13,382,250 02/11/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Feb 04 Option 19.6 2,702 52,959 46,729 02/04/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Feb 04 Sell 183.59 2,702 496,060 44,027 02/04/21
Daniels Mark See Remarks See Remarks Feb 01 Option 8.82 377 3,325 68,577 02/01/21
Daniels Mark See Remarks See Remarks Feb 01 Sell 161.02 377 60,705 68,200 02/01/21
Green Paula SVP of Human Resourc.. SVP of Human Resources Jan 26 Sell 193 246 47,478 22,250 01/26/21
Daniels Mark See Remarks See Remarks Jan 26 Option 23.33 620 14,465 68,820 01/26/21
Daniels Mark See Remarks See Remarks Jan 26 Sell 193 905 174,665 68,200 01/26/21
Banyai William See Remarks See Remarks Jan 26 Sell 192.95 14,099 2,720,402 461,937 01/26/21
Leproust Emily M. President & CEO President & CEO Jan 19 Sell 182.92 10,000 1,829,200 421,196 01/19/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Jan 07 Option 19.6 2,702 52,959 46,930 01/07/21
Finn Patrick John Chief Commercial Off.. Chief Commercial Officer Jan 07 Sell 132.93 2,702 359,177 44,228 01/07/21
Daniels Mark See Remarks See Remarks Dec 29 Option 16.08 997 16,032 69,164 12/29/20
Daniels Mark See Remarks See Remarks Dec 29 Sell 167.45 997 166,948 68,787 12/29/20